Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$12.14 USD
+0.09 (0.75%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $12.13 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Pliant Therapeutics, Inc. [PLRX]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; Phase 2b BEACON-IPF Trial Continues Enrollment; Week 24 INTEGRIS-PSC Data on Target in Mid-2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast Shows Promise in PSC But the Road Ahead Is Far From Clear; Key Value Proposition Remains IPF; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
320 mg Dose Effect in PSC Remains Positive Across Multiple Endpoints, but ELF Score Is Confounding; Trim PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; We Look For Late-Breaker at The Liver Meeting 2023 For Additional Data From INTEGRIS-PSC Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC Presentations Outline Rationale For PLN-101095''s Dual Inhibition of Integrins ava8/ava1 in Oncology
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Interim 12-Week Data From INTEGRIS-PSC Highly Encouraging and Better Than Expected; Raise PT to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast''s Potential in IPF Highlighted in ERS International Congress 2023; P2a INTEGRIS-PSC Data in 3Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Phase 2b BEACON-IPF Trial Kicks Off; Phase 2a INTEGRIS-PSC Data This Quarter; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fibrogen''s Pamrevlumab Exits the IPF Race With Phase 3 Miss; EASL Presentations Highlight Bexotegrast in PSC; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast''s Potential in IPF Highlighted at ATS 2023; Phase 2b BEACON-IPF to Start in Mid-2023 Start; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: Phase 2b BEACON-IPF Study to Start Mid-2023; Initial 12-Week Data in PSC in 3Q23; Moderate PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Data From Phase 2a INTEGRIS-IPF Study Further Highlights Bexotegrast''s Potential in IPF; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast 320 mg Demonstrates Durable Improvements in FVC, QLF and Cough at 24 Weeks; PT Nudged Up to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
American Thoracic Society International Conference Presentations Highlight Bexotegrast''s Potential in IPF; Affirm Buy.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Final Bexotegrast 320 mg Data Could Positively Surprise Again; Phase 2b IPF Trial Starts Mid-2023; Affirm Buy, PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: Data for 320 mg Dose in IPF in Early 1Q23; PSC Data in 3Q23; PLN-101095 to Enter the Clinic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Latest DSMB Review Confirmed PLN-74809''s Safety At 320 mg Top Dose; Early 2023 Interim Readout on Target; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Positive INTEGRIS-IPF Dataset Provides Strong Rationale to Advance PLN-74809 in IPF; Increasing PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Top-line Data From INTEGRIS-IPF Offers Strong Encouragement, But Appears Clouded by Variable Dose Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Data Presentation Highlights Novel Approach For Treatment of Muscular Dystrophies; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E